107. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects with Recurrent Vulvovaginal Candidiasis (ultraViolet)

BACKGROUND: Recurrent vulvovaginal candidiasis (RVVC) affects nearly 138 million women globally each year. Currently there are no FDA approved treatments. The study was conducted to evaluate the efficacy of oral oteseconazole (VT-1161) in the prevention of culture-verified acute VVC episodes through...

Descripción completa

Detalles Bibliográficos
Autores principales: Martens, Mark G, Maximos, Bassem, Degenhardt, Thorsten, Person, Karen, Curelop, Stacey, Ghannoum, Mahmoud, Brand, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644338/
http://dx.doi.org/10.1093/ofid/ofab466.107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644338/
http://dx.doi.org/10.1093/ofid/ofab466.107

Ejemplares similares